Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal

Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Diversified Dividend Stocks to Buy Right Now.

Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal

On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and development agreement with Johnson & Johnson (NYSE:JNJ) to support an experimental antibody treatment for autoimmune diseases. Shares of JNJ moved up nearly 0.7% in premarket trading following the news.

The agreement will run through 2026 and 2027 and focuses on the development of JNJ-4804. The therapy is designed to target IL-23 and TNF, two immune pathways that play a role in autoimmune inflammation. Royalty Pharma CEO Pablo Legorreta said the treatment shows promise for patients dealing with chronic immune-related conditions. He also pointed out that the deal builds on the company’s earlier work in immunology, including investments in therapies targeting TNF.

Royalty Pharma already collects royalties on more than 35 commercial products. That list includes Biogen’s Tysabri and Johnson & Johnson’s Tremfya, both widely used in autoimmune treatments.

Johnson & Johnson (NYSE:JNJ) operates across the healthcare space, with businesses spanning Innovative Medicine and MedTech. It focuses on developing, manufacturing, and selling a broad range of healthcare products.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Safest Stocks with Highest Dividends and Dividend Capture Strategy: 14 High Yield Stocks to Buy in April

Disclosure: None. Follow Insider Monkey on Google News.